Original Source(s)
Related Content
FDA Approves New First-Line TNBC Regimen
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
June 26, 2026
-
3 min
Nodular Fasciitis May Mimic Sarcoma
Molecular testing may help avoid overtreatment when benign soft-tissue tumors present with atypical clinical or histologic features.
May 11, 2026
-
4 min
Handwriting Kinematics Differentiate Cognitive Impairment
“Diagnostic differentiation emerged only under tasks imposing higher cognitive-motor demands.”
June 1, 2026
-
3 min